Abstract
Post-stroke depression (PSD) is a common complication after stroke. PSD is associated with emotional disorders and psychological dependence, which are potential risk factors for stroke recurrence and suicidality. This study aimed to perform an umbrella review of therapies for PSD through a comprehensive literature search. A systematic search was conducted in the PubMed and Web of Science by two independent authors. We examined the Hamilton Depression Scale (HAMD), Activities of daily living (ADL), Neurologic function as efficacy endpoints, and the incidence of adverse events as safety profiles. Seventeen eligible studies, including 267 clinical trials were included in this study. The results showed that High-Frequency Repetitive Transcranial Magnetic Stimulation (HfrTMS), Acupuncture/EA+conventional treatment, Escitalopram, Modified Sini San, Moxibustion, Xiaoyao Formula, Paroxetine, Chinese herbal medicine, Exercise, Citalopram, and Cognitive behavioral therapy are beneficial for improving the depression symptoms of patients with PSD. HfrTMS and Sertraline may have an impact on slowing the scores of activities of daily living or neurologic function. In addition, Acupuncture/EA+conventional, Escitalopram, Citalopram, Sertraline, and Fluoxetine showed no serious adverse events in PSD patients. Our study demonstrated that 11 treatment methods can effectively improve the condition of PSD patients.
Introduction
Stroke is a devastating disease causing significant neurologic disability, the second leading cause of death, and a major cause of long-term disability worldwide (Khoshnam et al., 2017). Post-stroke depression (PSD) is a common complication after stroke. It afflicts around 33% of stroke survivors and affects mortality rate, rehabilitation outcomes, and quality of life (Paolucci, 2017). In addition, emotional disorders and psychological dependence are potential risk factors for stroke recurrence and suicidality (Speranza et al., 2004).
The onset of PSD depends on psychosocial factors, the severity of the general vascular injury, stroke, and disability, and the interaction of other disorders (Göthe et al., 2012). The pathophysiology of PSD is closely related to vascular injury. There are many notable differences between PSD and major depression disorder (MDD): PSD has more serious depressive symptoms than MDD (Loubinoux et al., 2012); In addition, PSD shows more cognitive impairment and less sleep/circulation disturbance compared with MDD; The patients with PSD have a high prevalence of physical disabilities, such as aphasia, sensory loss, and motor/gait disorders (Cumming et al., 2010; Medeiros et al., 2020). In most cases, PSD occurs in the first month after the onset of stroke, tends to be chronic over time, and interferes with functional recovery (Arcadi et al., 2021). PSD limits participation in rehabilitation, reducing physical, social, and cognitive functions, and impairing neuroplasticity (Kutlubaev and Hackett, 2014). In addition, PSD increases the risk of mortality after stroke and recurrent stroke. The reduction of motivation-related PSD is considered to lead to the reduction of the motivation related to PSD, which in turn, leads to the reduction of the patient's willingness to adhere to preventive treatment (Miranda et al., 2018).
PSD is a common psychological complication of stroke, affecting about one-third of patients after stroke, harming the morbidity and mortality rates of patients.Therefore, it is important to develop effective post-stroke identification and treatment strategies. In addition, PSD is a common and complex psychiatric disease that delays the recovery of rehabilitation function and increases cognitive impairment. The etiology of PSD appears to be originated from physical and psychosocial stress, alone or in combination (Li et al., 2014). Furthermore, PSD negatively affects functional outcomes (Robinson and Jorge, 2016). The mechanism of PSD interferes with or affects functional recovery is considered to be the reduction of motivation and cognitive abilities (Vataja et al., 2001). There are several treatment strategies for PSD, including pharmacological and psychotherapy (Nabavi et al., 2014).
The clinical treatment of PSD is not exactly the same as MDD, which needs to be specifically approached. Pharmacotherapy and psychotherapy have traditionally been used in the treatment of PSD. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are frequently selected for the treatment of PSD. It is worth noting that SSRIs are first-choice drugs (Mortensen and Andersen, 2015), but many patients experience many adverse events with the treatment, such as the risk of bone fractures and nausea (Richter et al., 2021). Psychotherapy is commonly used in the treatment of PSD patients. Psychotherapy includes hfrTMS, problem-solving treatment, meridian acupoint massage, music therapy, exercise, motivational interview, and robot-assisted neural rehabilitation (Hadidi et al., 2017). The existing evidence shows that drug intervention and psychotherapy can prevent depression and improve the mood of PSD (Zhang et al., 2021c). However, the hfrTMS may increase the risk of seizures, and other psychotherapies are still inconclusive therapies for PSD (Wang et al., 2018; Frey et al., 2020). In addition, patients with PSD also consider seeking Traditional Chinese medicine (TCM) therapy as treatment, such as acupuncture (Hung et al., 2019), Chinese herbal medicines (Zhang et al., 2021a), and moxibustion (Guo et al., 2022). Increasing studies have been conducted to evaluate the therapeutic effect of TCM therapy on the treatment of PSD (Huang et al., 2018).
This study aims to provide an umbrella review of PSD therapies through a comprehensive literature search and to reach a clear conclusion by integrating the available meta-analyses and systematic reviews to identify an efficacious treatment for PSD patients that are commercially available.
Methods
Our study was performed under the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement (Moher et al., 2009).
Search strategy and quality assessment
Two independent authors conducted a preliminary screening in the PubMed and Web of Science to search for articles that contained search terms most related to our main construct of interest. The search terms were: (post-stroke depression) and (systematic review or meta-analysis). Meta-analyzed and systematic reviews of treatment methods for PSD patients were included in this study. Inclusion criteria were: (1) published in peer-reviewed journals until May 2022; (2) English-language literature; (3) published meta-analyses or systematic reviews; (4) participants in the general population. The studies were excluded if (1) duplicates; (2) unpublished studies; (3) not published in English; or (4) studies reported insufficient details and outcomes.
The meta-analyses and systematic reviews were evaluated using the AMSTAR tool (Shea et al., 2007). Studies were graded as low, medium, and high quality with an AMSTAR score of 0–4, 5–8, and 9–11, respectively.
Data extraction
The main characteristics of the selected studies were extracted in a table, including the first authors, publication year, number of studies, regimens for the treatment, and main outcomes. We included results with at least one of the assessment scales: (1) Hamilton Depression Scale (HAMD), (2) Activities of daily living (ADL), (3) Neurologic function, and (4) incidence of adverse events. Data extracted from studies include the number of studies, the number of patients, standardized mean difference/mean difference or Risk Ratio/odds ratio, and heterogeneity (I2).
Statistical analysis
The sample size and standardized mean difference/mean difference were calculated on the assessment scales. HAMD was used to provide an assessment indicator of depression and evaluate the effectiveness of the antidepressants for PSD. The NIHSS and ADL scales were performed to evaluate the neurologic function after stroke. The incidence of adverse events was assessed, and the Risk Ratio/ odds ratio was calculated. The selection of assessments was extracted on study size, sample size, standardized mean difference (SMD) /mean difference (MD) or relative ratio (RR) /odds ratio (OR), and heterogeneity (I2). The percentages of 0–25%, 26–50%, and 51–75% were classified as mild, moderate, and significant. If I2 > 50%, a random-effects model was used for the analysis, or the data was analyzed on the fixed-effects model.
Results
Literature search and study selection
Overall, a total of 291 records were identified from PubMed and Web of Science databases. Titles and abstracts were screened for full-text scrutiny. In all, 19 studies were excluded due to the following reasons: No necessary sample data (n = 8), Other outcomes (n = 5), Other reviews (n = 4), and Other languages (n = 2) (Figure 1). Thus, 17 studies were included in the umbrella review (Yi et al., 2010; Eng and Reime, 2014; Ren et al., 2015; Tan et al., 2015; Feng et al., 2018, 2022; Jin et al., 2018; Wang et al., 2018, 2021; Liu et al., 2019, 2021; Li et al., 2020; Cai et al., 2021; Lee et al., 2021; Zhang et al., 2021a,b; Guo et al., 2022). Study characteristics and quality ratings of 17 meta-analyses/systematic reviews were summarized in Table 1.
Figure 1
Table 1
| References | Conditions | Studies Included | Study duration | Type of included studies | Outcomes | AMSTAR scores | Study quality |
|---|---|---|---|---|---|---|---|
| Liu et al., 2019 | High-Frequency Repetitive Transcranial Magnetic Stimulation | 17 | 2-12W | RCTs | HAMD, BI or Modified Barthel Index, adverse events | 9/11 | High |
| Liu et al., 2021 | Acupuncture | 17 | 4W-6M | RCTs | HAMD | 8/11 | High |
| Feng et al., 2022 | Escitalopram | 11 | 4W-12M | RCTs | HAMD, Incidence of PSD, NIHSS, FM, Adverse events | 9/11 | High |
| Wang et al., 2021 | Electroacupuncture | 19 | 4-12W | RCTs | HAMD, Adverse events | 9/11 | Medium |
| Cai et al., 2021 | Modified sini san | 7 | 8W | RCTs | HAMD, Adverse events | 10/11 | High |
| Guo et al., 2022 | Moxibustion | 14 | 3-12W | RCTs | HAMD, MESSS, effective rate | 9/11 | High |
| Jin et al., 2018 | XIAOYAO FORMULA | 7 | 2-8W | RCTs | HAMD, Adverse events | 7/11 | High |
| Li et al., 2020 | Paroxetine | 4 | 4-12W | RCTs | HAMD | 9/11 | High |
| Feng et al., 2018 | Sertraline | 11 | 6-52W | RCTs | HAMD, Incidence of PSD, NIHSS, BI, Adverse events | 9/11 | High |
| Zhang et al., 2021a | Chinese herbal medicines | 18 | 4-12W | RCTs | HAMD, SSS | 10/11 | High |
| Eng and Reime, 2014 | Exercise | 13 | 4-13W | RCTs | HAMD, GDS, CES | 8/11 | High |
| Lee et al., 2021 | Non-Pharmacological Interventions | 13 | 12-16W | RCTs | HAMD | 8/11 | High |
| Ren et al., 2015 | Herbal medicine | 26 | 1-8W | RCTs | HAMD | 9/11 | High |
| Tan et al., 2015 | Citalopram | 48 | 2-12W | RCTs | HAMD | 10/11 | High |
| Wang et al., 2018 | Cognitive behavioral therapy | 23 | 2-40W | RCTs | HAMD, SDS | 10/11 | High |
| Yi et al., 2010 | Fluoxetine for the prophylaxis | 6 | 4-12W | RCTs | HAMD, Adverse events | 9/11 | High |
| Zhang et al., 2021b | Acupuncture combined with antidepressants | 13 | 4-8W | RCTs | HAMD, NIHSS, BI | 9/11 | High |
Description of included studies.
Depression rating scores
From our search, all 17 studies included the depression rating scores of the treatments in the HAMD score (Table 2). High-Frequency Repetitive Transcranial Magnetic Stimulation (hfrTMS; SMD: −1.01, 95%CI −1.36 – −0.66), Acupuncture/EA+conventional treatment (SMD: −2.72, 95%CI −3.61 – −1.82), Escitalopram (SMD: −1.15, 95%CI −2.21 – −0.09), Modified Sini San (MD: −6.68, 95%CI −9.22 – −4.14), Moxibustion (MD: −1.17, 95%CI −1.55 – −0.79), Xiaoyao Formula (MD: −5.21, 95%CI −7.48 – −2.95), Paroxetine (MD: −9.79, 95%CI −16.94 – −2.64), Chinese herbal medicine (MD: −3.17, 95%CI −4.12 – −2.22), Exercise (SMD: −0.13, 95%CI −0.26 – −0.01), Citalopram (MD: −0.43, 95%CI −0.85 – −0.01), Cognitive behavioral therapy (SMD: −0.76, 95%CI −1.22 – −0.29), showed better outcomes compared to the controls that received antidepressants such as other SSRIs, TCMs, TCAs, and placebo.
Table 2
| Pairwise meta-analyses | ||||||||
|---|---|---|---|---|---|---|---|---|
| Comparative medications | Reference medications | Number of studies | Number of patients | SMD | MD | 95% CI | I2 | P-value |
| High-Frequency Repetitive Transcranial Magnetic Stimulation | Control | 15 | 1053 | −1.01 | [−1.36, −0.66] | 85 | P < 0.00001 | |
| Acupuncture/EA+ conventional | Conventional treatment | 2 | 157 | −2.72 | [−3.61, −1.82] | 0 | P < 0.00001 | |
| Acupuncture/EA (+placebo) | Antidepressants (+sham acupuncture) | 4 | 494 | −1.55 | [−4.36, 1.26] | 95 | P ≤ 0.28 | |
| Escitalopram | Control | 4 | 320 | −1.15 | [−2.21, −0.09] | 95 | P < 0.00001 | |
| Electroacupuncture | Antidepressants | 19 | 1572 | −0.04 | [ −0.16, 0.07] | 0 | P = 0.69 | |
| Modified sini san | Control | 6 | 468 | −6.68 | [ −9.22, −4.14] | 97 | P < 0.00001 | |
| Moxibustion | Control | 14 | 863 | −1.17 | [−1.55, −0.79] | 86 | P < 0.00001 | |
| Xiaoyao Formula | Antidepressants | 7 | 607 | −5.21 | [−7.48, −2.95] | 97 | P < 0.00001 | |
| Paroxetine | Control | 2 | 98 | −9.79 | [−16.94, −2.64] | 95 | P = 0.007 | |
| Chinese herbal medicine | Control | 15 | 1367 | −3.17 | [ −4.12, −2.22] | 87 | P < 0.001 | |
| Exercise | Control | 13 | 1022 | −0.13 | [ −0.26, −0.01] | 6 | P = 0.03 | |
| Citalopram | Other SSRIs | 9 | 624 | −0.43 | [−0.85, −0.01] | 85 | P = 0.00 | |
| Citalopram | TCAs | 12 | 700 | −0.31 | [−0.50, −0.12] | 35 | P = 0.11 | |
| Citalopram | TCMs | 4 | 285 | 0.22 | [ −0.20, −0.65] | 69 | P=0.02 | |
| No antidepressants | Control | 7 | 859 | −0.76 | [−1.22, −0.29] | 91 | P = 0.001 | |
| Use of antidepressants | Control | 14 | 970 | −0.95 | [−1.20, −0.71] | 69 | P < 0.00001 | |
| Some patients used antidepressants | Control | 2 | 143 | −0.2 | [−0.53, 0.13] | 0 | P = 0.24 | |
| Fluoxetine | Control | 4 | 217 | −3.97 | [−9.85, 1.90] | 97 | P = 0.19 | |
| Manual acupuncture +antidepressants | Control | 6 | 483 | −3.54 | [−4.54, −2.55] | 60 | P < 0.00001 | |
| Electroacupuncture +antidepressants | Control | 7 | 421 | −3.66 | [−4.58, −2.74] | 28 | P < 0.00001 | |
Results of pairwise meta-analyses for HAMD.
Activities of daily living
Table 3 presents the results of the effects of the treatments on activities of daily living. ADL scores assessed; only 2 studies. The results revealed that hfrTMS (MD: 1.09, 95% CI: 0.34–1.84) and Sertraline (MD: 11.48, 95% CI: 4.18–18.78) led to greater improvement than control group.
Table 3
| Pairwise meta-analyses | |||||||
|---|---|---|---|---|---|---|---|
| Comparative medications | Reference medications | Number of studies | Number of patients | MD | 95% CI | I2 | P-value |
| High-Frequency Repetitive | Control | 3 | 313 | 1.09 | [0.34, 1.84] | 89 | P = 0.004 |
| Transcranial Magnetic | |||||||
| Stimulation | |||||||
| Sertraline | Control | 7 | 1032 | 11.48 | [ 4.18, 18.78] | 97 | P = 0.002 |
Results of pairwise meta-analyses for ADL.
Neurologic function
The effects of the treatments on neurologic function were assessed by NIHSS (Table 4). Patients administered with hfrTMS (MD: −0.91, 95% CI: −1.19 – −0.63), Sertraline (MD: −3.44, 95% CI: −6.66 – −0.21), and Fluoxetine (MD: −4.72, 95% CI: −8.31 – −1.13) showed better neurologic function than the control.
Table 4
| Pairwise meta-analyses | |||||||
|---|---|---|---|---|---|---|---|
| Comparative medications | Reference medications | Number of studies | Number of patients | MD | 95% CI | I2 | P-value |
| High-Frequency Repetitive | Control | 4 | 221 | −0.91 | [−1.19, −0.63] | 0 | P < 0.00001 |
| Transcranial Magnetic | |||||||
| Stimulation | |||||||
| Sertraline | Control | 4 | 328 | −3.44 | [−6.66, −0.21] | 82 | P = 0.04 |
| Fluoxetine | Control | 2 | 157 | −4.72 | [−8.31, −1.13] | 82 | P = 0.01 |
Results of pairwise meta-analyses for neurologic function.
Adverse events
The studies of patients with adverse events performed a beneficial effect of Acupuncture/EA(+placebo) (RR: 0.16, 95% CI: 0.07–0.39), Electroacupuncture (RR: 0.21, 95% CI: 0.14–0.32), Modified Sini San (OR = 0.12, 95% CI: 0.06–0.24), and Chinese herbal medicine (RR: 0.49, 95% CI: 0.31–0.77) treatment compared to control group. In addition, there were no significant differences between Acupuncture/EA+conventional, Escitalopram, Citalopram, Sertraline, Fluoxetine, and the control group in adverse events (Table 5).
Table 5
| Pairwise meta-analyses | ||||||||
|---|---|---|---|---|---|---|---|---|
| Comparative medications | Reference medications | Number of studies | Number of patients | RR | OR | 95% CI | I2 | P-value |
| Acupuncture/EA + conventional | conventional treatment | 2 | 158 | 0.63 | [0.21, 1.83] | 38 | P = 0.39 | |
| Acupuncture/EA (+placebo) | antidepressants (+sham acupuncture) | 5 | 296 | 0.16 | [0.07, 0.39] | 35 | P < 0.00001 | |
| Escitalopram | Control | 7 | 996 | 1.31 | [0.86, 1.99] | 59 | P = 0.21 | |
| Electroacupuncture | Antidepressants | 9 | 859 | 0.21 | [0.14, 0.32] | 0 | P < 0.00001 | |
| Modified sini san | Control | 4 | 310 | 0.12 | [0.06, 0.24] | 37 | P < 0.00001 | |
| Citalopram | Other SSRIs | 7 | 510 | 0.85 | [0.65, 1.10] | 0 | P = 0.21 | |
| Citalopram | SNRIs | 4 | 282 | 0.95 | [ 0.71, 1.26] | 0 | P=0.70 | |
| Sertraline | Control | 11 | 4657 | 0.94 | [0.83, 1.06] | 45 | P = 0.33 | |
| Chinese herbal medicine | Control | 11 | NA | 0.49 | [0.31, 0.77] | 50 | P = 0.03 | |
| Fluoxetine | Control | 3 | 158 | 0.88 | [0.31, 2.49] | 0 | P = 0.82 | |
Results of pairwise meta-analyses for adverse events.
Discussion
Our umbrella review was conducted by usingthe data derived from treatments of PSD patients, which was used to appraise the relative effectiveness of therapy. We attempted to summarize data from published meta-analyses and systematic reviews to indicate that there are significant beneficial treatment in patients with PSD.
The main theories of PSD are the neurotransmitter and cytokine hypotheses (Santos et al., 2009). Depression is associated with low levels of monoamines, especially 5-hydroxytryptamine, Norepinephrine, and dopamine (Krishnan and Nestler, 2008). Different symptoms of depression (cognition, emotion, and pain) may be related to the diverse neural systems. Changes in the limbic reward system of the dopaminergic midbrain may lead to the absence of delight hedonia (Nestler and Carlezon, 2006). Noradrenergic and serotonergic fibers originate from the brain stem nucleus and dominate the limbic system, prefrontal cortex, and related structures involved in emotion regulation. In addition, the descending pathway regulates pain through dorsolateral spinal protrusion. Furthermore, the cholinergic system has been considered related to the etiology of depression through nicotinic acetylcholine receptors. These pathways are associated with stroke lesions, leading to depression (Mineur and Picciotto, 2010). Antidepressants directly affect the brain or beyond their effects on depression, which may provide neuroprotection and promote brain neurogenesis (Loubinoux et al., 2012). Previous studies have indicated that SSRIs have beneficial effects on functional independence in PSD patients (Mead et al., 2012). Therefore, SSRIs were commonly used as a positive drug to ensure the sensitivity of the treatment for PSD.
It is speculated that low-frequency TMS stimulates inhibitory neurons while hfrTMS stimulates excitatory projection neurons, thus simulating neural plasticity through long-term enhancement (Duan et al., 2018). Therapy's benefits may be achieved by enhancing neuroplasticity, increasing the available concentration of key neurotransmitters, strengthening the positive emotional connection network, and reducing the connection in the negative emotional loops (Nordmann et al., 2015). Studies have shown that hfrTMS increases the concentration of BDNF, glucose metabolism in the cortex, neurogenesis, and regulation of neurobiochemical effects (Duan et al., 2018). Moreover, traditional Chinese medicine has the characteristics of multi-target and multi-pathway. Traditional Chinese medicine activates blood circulation, dissipates blood stasis, sedation, and hypnosis for patients with blood stasis syndrome, insomnia, and anxiety after stroke. It increases the secretion of neurotransmitters and 5-hydroxytryptophan and is widely used to treat PSD (Ding et al., 2021; Wan et al., 2021). Effective moxibustion is divided into four aspects: warming effect, medicinal penetration, infrared radiation, and aromatherapy (Huang et al., 2017). Long-term moxibustion can promote the'brain's uptake of L-tryptophan and shift L-tryptophan metabolism to 5-Hydroxytryptamine (Li et al., 2019). Previous studies have suggested that exercise is a complementary treatment for depression (De Man-Van Ginkel et al., 2010). Exercise may affect the hypothalamic-pituitary-adrenal (HPA) axis and immune function, improve the regulation of HPA response and increase immunity (Sigwalt et al., 2011). Cognitive-behavioral therapy can identify the emotional state of patients, overcome emotional disabilities, and treat depression and anxiety in PSD (Eum and Yim, 2015). Moreover, we considered the treatment with hfrTMS, Acupuncture/EA+conventional treatment, Escitalopram, Modified Sini San, Moxibustion, Xiaoyao Formula, Paroxetine, Chinese herbal medicine, Exercise, Citalopram, and Cognitive behavioral therapy to have a beneficial effect on PSD.
The safety of the treatments is critical in the treatment of PSD. The number of participants with at least one adverse event such as gastrointestinal symptoms, nausea, headache, insomnia, cardiovascular events, and other disorders was extracted. In addition, in the present review, the incidence of withdrawals as a result of adverse events with Acupuncture/EA(+placebo), Electroacupuncture, Modified Sini San, and Chinese herbal medicine treatments tended to be lower than control groups. Moreover, our study summarized that there were no significant differences between Acupuncture/EA+conventional, Escitalopram, Citalopram, Sertraline, Fluoxetine, and the control group in adverse events.
Limitations
First, the comparative evidence of PSD treatments in this study was relatively small. Second, there may be other factors that may lead to this study's inconsistencies, such as the quality of the researched studies. Furthermore, a considerable number of researchers lack the abovementioned data, which makes less studies available.
Conclusion
In conclusion, we found that 11 treatment methods may effectively improve the condition of PSD patients. In the future, patients with PSD should be treated with significant beneficial therapies, contributing to the successful construction of similar studies.
Funding
This study was supported by the experimental animal project of Zhejiang Basic Public Welfare Research Program (No. LGD20H090001), the Natural Science Foundation of Huzhou city (No.2018YZ03), the National Natural Science Foundation, China (No. 82004078), the Natural Science Foundation of Shandong Province (ZR2021LZY018).
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.
Author contributions
JX and XG collected the data. JX, TL, XF, and FF analyzed the data and prepared tables. JX wrote the manuscript. TL and SH designed the research. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
ArcadiF. A.CoralloF.TorrisiM.ScarfìC.Lo BuonoV.FormicaC.et al. (2021). Role of citicoline and choline in the treatment of post-stroke depression: an exploratory study. J. Int. Med. Res.49, 1–7. 10.1177/03000605211055036
2
CaiL.JiejieL.HuY.ChenW.WeiL.HeQ.et al. (2021). Efficacy and safety of modified Sini San for treating poststroke depression: a meta-analysis of randomized controlled trials. Explore (NY)17, 162–169. 10.1016/j.explore.2020.05.008
3
CummingT. B.ChurilovL.SkoogI.BlomstrandC.LindenT. (2010). Little evidence for different phenomenology in poststroke depression. Acta Psychiatr. Scand.121, 424–430. 10.1111/j.1600-0447.2010.01558.x
4
De Man-Van GinkelJ. M.GooskensF.SchuurmansM. J.LindemanE.HafsteinsdottirT. B. (2010). A systematic review of therapeutic interventions for poststroke depression and the role of nurses. J. Clin. Nurs.19, 3274–3290. 10.1111/j.1365-2702.2010.03402.x
5
DingC.XuM.GaoL.WangX.XuW.GuoM.et al. (2021). Clinical efficacy of Danzhi Xiaoyao Powder in the treatment of post-stroke depression: a protocol for randomized, double-blind clinical study. Medicine (Baltimore)100, e27318. 10.1097/MD.0000000000027318
6
DuanX.YaoG.LiuZ.CuiR.YangW. (2018). Mechanisms of transcranial magnetic stimulation treating on post-stroke depression. Front. Hum. Neurosci.12, 215. 10.3389/fnhum.2018.00215
7
EngJ. J.ReimeB. (2014). Exercise for depressive symptoms in stroke patients: a systematic review and meta-analysis. Clin. Rehabil.28, 731–739. 10.1177/0269215514523631
8
EumY.YimJ. (2015). Literature and art therapy in post-stroke psychological disorders. Tohoku J. Exp. Med.235, 17–23. 10.1620/tjem.235.17
9
FengR.WangP.GaoC.YangJ.ChenZ.YangY.et al. (2018). Effect of sertraline in the treatment and prevention of poststroke depression: a meta-analysis. Medicine (Baltimore)97, e13453. 10.1097/MD.0000000000013453
10
FengR. F.MaR.WangP.JiX.ZhangZ. X.LiM. M.et al. (2022). Efficacy of escitalopram for poststroke depression: a systematic review and meta-analysis. Sci. Rep.12, 3304. 10.1038/s41598-022-05560-w
11
FreyJ.NajibU.LillyC.AdcockA. (2020). Novel TMS for Stroke and Depression (NoTSAD): accelerated repetitive transcranial magnetic stimulation as a safe and effective treatment for post-stroke depression. Front. Neurol.11, 788. 10.3389/fneur.2020.00788
12
GötheF.EnacheD.WahlundL. O.WinbladB.CrisbyM.LökkJ.et al. (2012). Cerebrovascular diseases and depression: epidemiology, mechanisms and treatment. Panminerva Med.54, 161–170. 10.1055/s-0032-1305312
13
GuoS. Q.ZhaoG. Z.LiS. T.YaoQ.HanL.LiB.et al. (2022). Moxibustion for treating patients with post-stroke depression: a systematic review and meta-analysis. Ann. Palliat. Med.11, 85–97. 10.21037/apm-21-3421
14
HadidiN. N.Huna WagnerR. L.LindquistR. (2017). Nonpharmacological treatments for post-stroke depression: an integrative review of the literature. Res. Gerontol. Nurs.10, 182–195. 10.3928/19404921-20170524-02
15
HuangK.LiangS.SunZ.ZhangJ. (2017). Startup mechanism of moxibustion warming and dredging function. Zhongguo Zhen Jiu37, 1023–1026. 10.13703/j.0255-2930.2017.09.031
16
HuangW.LiaoX.TianJ.WuJ.ShanY.ZhouW. (2018). Traditional Chinese medicine for post-stroke depression: a systematic review and network meta-analysis (Protocol). Medicine (Baltimore)97, e13840. 10.1097/MD.0000000000013840
17
HungC. Y.WuX. Y.ChungV. C.TangE. C.WuJ. C.LauA. Y. (2019). Overview of systematic reviews with meta-analyses on acupuncture in post-stroke cognitive impairment and depression management. Integr. Med. Res.8, 145–159. 10.1016/j.imr.2019.05.001
18
JinX.JiangM.GongD.ChenY.FanY. (2018). Efficacy and safety of xiaoyao formula as an adjuvant treatment for post-stroke depression: a meta-analysis. Explore (NY)14, 224–229. 10.1016/j.explore.2017.12.007
19
KhoshnamS. E.WinlowW.FarzanehM.FarboodY.MoghaddamH. F. (2017). Pathogenic mechanisms following ischemic stroke. Neurol. Sci.38, 1167–1186. 10.1007/s10072-017-2938-1
20
KrishnanV.NestlerE. J. (2008). The molecular neurobiology of depression. Nature455, 894–902. 10.1038/nature07455
21
KutlubaevM. A.HackettM. L. (2014). Part II: predictors of depression after stroke and impact of depression on stroke outcome: an updated systematic review of observational studies. Int. J. Stroke9, 1026–1036. 10.1111/ijs.12356
22
LeeY.ChenB.FongM. W. M.LeeJ. M.NicolG. E.LenzeE. J.et al. (2021). Effectiveness of non-pharmacological interventions for treating post-stroke depressive symptoms: Systematic review and meta-analysis of randomized controlled trials. Top. Stroke Rehabil.28, 289–320. 10.1080/10749357.2020.1803583
23
LiH.SangL.XiaX.ZhaoR.WangM.HouX.et al. (2019). Therapeutic duration and extent affect the effect of moxibustion on depression-like behaviour in rats via regulating the brain tryptophan transport and metabolism. Evid. Based Complement. Alternat. Med.2019, 7592124. 10.1155/2019/7592124
24
LiL.HanZ.LiL.HanL.YanB. (2020). Effectiveness of paroxetine for poststroke depression: a meta-analysis. J. Stroke Cerebrovasc. Dis.29, 104664. 10.1016/j.jstrokecerebrovasdis.2020.104664
25
LiW.LingS.YangY.HuZ.DaviesH.FangM. (2014). Systematic hypothesis for post-stroke depression caused inflammation and neurotransmission and resultant on possible treatments. Neuro Endocrinol. Lett.35, 104–109.
26
LiuC.WangM.LiangX.XueJ.ZhangG. (2019). Efficacy and safety of high-frequency repetitive transcranial magnetic stimulation for poststroke depression: a systematic review and meta-analysis. Arch. Phys. Med. Rehabil.100, 1964–1975. 10.1016/j.apmr.2019.03.012
27
LiuR.ZhangK.TongQ. Y.CuiG. W.MaW.ShenW. D. (2021). Acupuncture for post-stroke depression: a systematic review and meta-analysis. BMC Complement. Med. Ther.21, 109. 10.1186/s12906-021-03277-3
28
LoubinouxI.KronenbergG.EndresM.Schumann-BardP.FreretT.FilipkowskiR. K.et al. (2012). Post-stroke depression: mechanisms, translation and therapy. J. Cell Mol. Med.16, 1961–1969. 10.1111/j.1582-4934.2012.01555.x
29
MeadG. E.HsiehC. F.LeeR.KutlubaevM. A.ClaxtonA.HankeyG. J.et al. (2012). Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst. Rev.11, Cd009286. 10.1002/14651858.CD009286.pub2
30
MedeirosG. C.RoyD.KontosN.BeachS. R. (2020). Post-stroke depression: a 2020 updated review. Gen. Hosp. Psychiatry66, 70–80. 10.1016/j.genhosppsych.2020.06.011
31
MineurY. S.PicciottoM. R. (2010). Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol. Sci.31, 580–586. 10.1016/j.tips.2010.09.004
32
MirandaJ. J.MoscosoM. G.ToyamaM.CaveroV.Diez-CansecoF.OvbiageleB. (2018). Role of mHealth in overcoming the occurrence of post-stroke depression. Acta Neurol. Scand.137, 12–19. 10.1111/ane.12832
33
MoherD.LiberatiA.TetzlaffJ.AltmanD. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med.6, e1000097. 10.1371/journal.pmed.1000097
34
MortensenJ. K.AndersenG. (2015). Safety of selective serotonin reuptake inhibitor treatment in recovering stroke patients. Expert Opin Drug Saf.14, 911–919. 10.1517/14740338.2015.1033396
35
NabaviS. F.TurnerA.DeanO.SuredaA.MohammadS. (2014). Post-stroke depression therapy: where are we now?Curr. Neurovasc. Res.11, 279–289. 10.2174/1567202611666140522123504
36
NestlerE. J.CarlezonW. A.Jr (2006). The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry59, 1151–1159. 10.1016/j.biopsych.2005.09.018
37
NordmannG.AzorinaV.LangguthB.SchecklmannM. (2015). A systematic review of non-motor rTMS induced motor cortex plasticity. Front. Hum. Neurosci.9, 416. 10.3389/fnhum.2015.00416
38
PaolucciS. (2017). Advances in antidepressants for treating post-stroke depression. Expert Opin. Pharmacother.18, 1011–1017. 10.1080/14656566.2017.1334765
39
RenY.ZhuC.WuJ.ZhengR.CaoH. (2015). Comparison between herbal medicine and fluoxetine for depression: a systematic review of randomized controlled trials. Complement. Ther. Med.23, 674–684. 10.1016/j.ctim.2015.07.002
40
RichterD.Charles JamesJ.EbertA.KatsanosA. H.Mazul-WachL.RulandQ.et al. (2021). Selective serotonin reuptake inhibitors for the prevention of post-stroke depression: a systematic review and meta-analysis. J. Clin. Med.10, 5912. 10.3390/jcm10245912
41
RobinsonR. G.JorgeR. E. (2016). Post-stroke depression: a review. Am. J. Psychiatry173, 221–231. 10.1176/appi.ajp.2015.15030363
42
SantosM.KövariE.GoldG.BozikasV. P.HofP. R.BourasC.et al. (2009). The neuroanatomical model of post-stroke depression: towards a change of focus?J. Neurol. Sci.283, 158–162. 10.1016/j.jns.2009.02.334
43
SheaB. J.GrimshawJ. M.WellsG. A.BoersM.AnderssonN.HamelC.et al. (2007). Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med. Res. Methodol.7, 10. 10.1186/1471-2288-7-10
44
SigwaltA. R.BuddeH.HelmichI.GlaserV.GhisoniK.LanzaS.et al. (2011). Molecular aspects involved in swimming exercise training reducing anhedonia in a rat model of depression. Neuroscience192, 661–674. 10.1016/j.neuroscience.2011.05.075
45
SperanzaM.CorcosM.StéphanP.LoasG.Pérez-DiazF.LangF.et al. (2004). Alexithymia, depressive experiences, and dependency in addictive disorders. Subst. Use Misuse39, 551–579. 10.1081/JA-120030058
46
TanS.HuangX.DingL.HongH. (2015). Efficacy and safety of citalopram in treating post-stroke depression: a meta-analysis. Eur. Neurol.74, 188–201. 10.1159/000441446
47
VatajaR.PohjasvaaraT.LeppävuoriA.MäntyläR.AronenH. J.SalonenO.et al. (2001). Magnetic resonance imaging correlates of depression after ischemic stroke. Arch. Gen. Psychiatry58, 925–931. 10.1001/archpsyc.58.10.925
48
WanR.SongR.FanY.LiL.ZhangJ.ZhangB.et al. (2021). Efficacy and safety of Chaihu Jia Longgu Muli decoction in the treatment of poststroke depression: a systematic review and meta-analysis. Evid. Based Complement. Alternat. Med.2021, 7604537. 10.1155/2021/7604537
49
WangS. B.WangY. Y.ZhangQ. E.WuS. L.NgC. H.UngvariG. S.et al. (2018). Cognitive behavioral therapy for post-stroke depression: a meta-analysis. J. Affect. Disord.235, 589–596. 10.1016/j.jad.2018.04.011
50
WangX.CaiW.WangY.HuangS.ZhangQ.WangF. (2021). Is electroacupuncture an effective and safe treatment for poststroke depression? An updated systematic review and meta-analysis. Biomed Res. Int.2021, 8661162. 10.1155/2021/8661162
51
YiZ. M.LiuF.ZhaiS. D. (2010). Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis. Int. J. Clin. Pract.64, 1310–1317. 10.1111/j.1742-1241.2010.02437.x
52
ZhangH.LiM.XuT. (2021a). Therapeutic effect of Chinese herbal medicines for post-stroke depression: A meta-analysis of randomized controlled trials. Medicine (Baltimore)100, e24173. 10.1097/MD.0000000000024173
53
ZhangK.CuiG.GaoY.ShenW. (2021b). Does acupuncture combined with antidepressants have a better therapeutic effect on post-stroke depression? A systematic review and meta-analysis. Acupunct. Med.39, 432–440. 10.1177/0964528420967675
54
ZhangW.LiuY.YuJ.ZhangQ.WangX.ZhangY.et al. (2021c). Exercise interventions for post-stroke depression: a protocol for systematic review and meta-analysis. Medicine (Baltimore)100, e24945. 10.1097/MD.0000000000024945
Summary
Keywords
post-stroke depression, meta-analysis, systematic review, umbrella review, therapies
Citation
Xie J, Geng X, Fan F, Fu X, He S and Li T (2022) The efficacy of therapies for post-stroke depression in aging: An umbrella review. Front. Aging Neurosci. 14:993250. doi: 10.3389/fnagi.2022.993250
Received
13 July 2022
Accepted
08 August 2022
Published
23 August 2022
Volume
14 - 2022
Edited by
Ming Chen, ShanghaiTech University, China
Reviewed by
Ting Shen, Zhejiang University Interdisciplinary Institute of Neuroscience and Technology (ZIINT), China; Xiaona Zhu, ShanghaiTech University, China
Updates
Copyright
© 2022 Xie, Geng, Fan, Fu, He and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shuaibing He 02863@zjhu.edu.cnTao Li 02606@zjhu.edu.cn
†These authors share first authorship
This article was submitted to Neurocognitive Aging and Behavior, a section of the journal Frontiers in Aging Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.